Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19.

ABSTRACT:

Introduction

Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the era of Omicron and sub-variants.

Methods

Our retrospective study aimed to compare the safety profile and effectiveness of the two antivirals in all consecutive high-risk outpatients between 11 January and 10 July 2022. A logistic regression model was carried out to assess factors associated with the composite outcome defined as all-cause hospitalization and/or death at 30 days.

Results

A total of 719 individuals were included: 554 (77%) received Molnupiravir, whereas 165 (2

SUBMITTER: Bruno G 

PROVIDER: S-EPMC9695104 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature